TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05270785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAT-PC
Description: STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management (2-3 follow-up calls). The intervention will consist of an initial session with the youth focusing on accessing mental health care plus two case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to two months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YST-III
Description: YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate 1-2 supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 2 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 2 months.
Study: NCT05617651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-NT-T
Description: Ilaprazole 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-NT-T
Description: Ilaprazole 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-NT-R
Description: Ilaprazole 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-NT-R
Description: Ilaprazole 10mg
Study: NCT06341153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Milk Odor Stimulation
Description: In the breast milk odor stimulation group, one or two drops of breast milk were placed on a sponge in accordance with the literature. Breast milk was obtained from each infant's own mother by hand expressing. The mothers were asked to express two drops of breast milk from their breasts onto the sponge. The sponge on which the breast milk was dripped was placed as close to the baby's nose as possible without touching the baby's nose. Since breast milk odor stimulation is recommended to be given to the baby for 1 minute in the literature, the baby was allowed to smell the odor of breast milk for 1 minute. The baby was then given to the mother for breastfeeding and breastfeeding was initiated as in routine practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulation of Breast Milk Smell and Taste
Description: In this group in which the breast milk sniffing method was applied; two drops of breast milk were dripped onto a sponge in accordance with the literature and this sponge was placed as close to the nose as possible without touching the nose and the baby was allowed to smell the smell of breast milk for about 1 minute. Then the baby was given to the mother. The mother was asked to express milk manually and to apply/drip approximately 0.2 ml (approximately two drops) of the expressed colostrum starting from the tip of the baby's tongue, along the tongue surface, on both cheeks of the baby, as applied in studies using oral colostrum as a reference. The mother was also asked to express a drop of milk from her breast and manually apply it to the areola. Breastfeeding was then initiated as in routine practice.
Study: NCT05267860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophylactic Drain
Description: We want to put a prophylactic drain after cholecystectomy.
Study: NCT05433350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acoziborole
Description: Two different formulations will be used during the study depending on the body weight and on the step of the study:~Tablets of 320 mg dose for paediatric patients weighing 30 to 40 kg in step 1 Granules in bottle of 160 mg for paediatric patients weighing 10 to 40 kg in step 2
Study: NCT06044402

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: group L (Vt 6 ml/kg)
Description: low tidal volume ventilation (tidal volume was set to 6 ml/kg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group I (Vt 8 ml/kg)
Description: intermediate tidal volume ventilation (tidal volume was set to 8 ml/kg)
Study: NCT05665088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501
Description: Sublingual Film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501
Description: Sublingual Film

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Sublingual Placebo Film
Study: NCT05424003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: Starting dose of 0.24 mg injected weekly and increased every 4 weeks to a potential maximum dose of 2.4 mg weekly at 20 weeks followed by 52 weeks of weekly injections at the maximum tolerable dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution injected weekly for 72 weeks
Study: NCT04242589

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: External beam radiation therapy is a type of radiation therapy used for cancer treatment. A machine is used to aim high-energy rays from outside the body into tumor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: External beam radiation therapy is a type of radiation therapy used for cancer treatment. A machine is used to aim high-energy rays from outside the body into tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebropladty
Description: Vertebroplasty is a procedure for stabilizing compression fractures in the spine. Bone cement is injected into vertebrae that have cracked or broken. The cement hardens, stabilizing the fractures and supporting your spine.
Study: NCT06419751

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular exercise
Description: Based on the study participant's status and exercise assessment, the investigators prescribe moderate-intensity aerobic exercise combined with resistance exercise. Before each exercise, preparatory activities (10min), 20-30min moderate-intensity aerobic exercise, finishing activities (10min) at the end, 5 days/week, for 12 weeks, and at the same time, choose non-consecutive 3 days of resistance training in 5 aerobic training sessions to increase resistance training (choose 1\~2 muscle groups each time, 4\~5 movements, repeat each action 8\~12 times, repeat 2\~3 sets)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin
Description: A professional therapist instructed the participants to learn and train Baduanjin before the intervention, and a standardized Baduanjin exercise program included eight postures, each training time was about 50 minutes (including 10 min of warm-up, 2 times of Baduanjin, and 10 min of relaxation), 5 days/week, a total of 12 weeks
Study: NCT05141123

Intervention type: PROCEDURE
Intervention: Complex Endovascular Aortic Procedures treated by Preloaded Fenestrated Stent-graft Designs for
Description: Evaluate the outcomes of the preloaded stent-graft design (PLD) in the routine treatment of para-renal and thoraco-abdominal aneurysms
Study: NCT02776345

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Needle Fragmentation
Description: Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: US guided needle fragmentation & Lavage
Description: Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound guided subacromial injection
Description: Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
Study: NCT06026228

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri
Description: The BioGaia® Gastrus probiotic capsule contains the following components: L. reuteri DSM 17938, L. reuteri ATCC PTA 6475) at 10\^8 CFU\*/day, fully hydrogenated palm oil; ascorbic acid; tangerine flavour and mint flavour.~\*Colony forming Unit

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules have the same external appearance and composition as the BioGaia® Gastrus Limosilactobacillus reuteri probiotic capsule (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475), but without the active ingredient.
Study: NCT05116852

Intervention type: OTHER
Intervention: Survey
Description: All study participants will be asked to complete two surveys relevant to their personal experience either losing a loved one to opioid-related death, supporting a loved on in recovery for Opioid Use Disorder, or both.

Intervention type: OTHER
Intervention: Survey
Description: All study participants will be asked to complete two surveys relevant to their personal experience either losing a loved one to opioid-related death, supporting a loved on in recovery for Opioid Use Disorder, or both.

Intervention type: OTHER
Intervention: Survey
Description: All study participants will be asked to complete two surveys relevant to their personal experience either losing a loved one to opioid-related death, supporting a loved on in recovery for Opioid Use Disorder, or both.
Study: NCT01189032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-089 ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-089 ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution
Study: NCT06516679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation #4(without daunorubicin)
Description: 1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. Low Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, intrathecal methotrexate~3. Low Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. Low Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. Low Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Maintenance chemotherapy(about 2yrs) : Vincristine, Dexamethasone, 6-mercaptopurine, intrathecal methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation #4(with daunorubicin)
Description: 1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. High Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, Daunorubicin intrathecal methotrexate~3. High Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. High Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. High Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Maintenance chemotherapy(about 2yrs) : Vincristine, Dexamethasone, 6-mercaptopurine, intrathecal methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation after Consolidation #4(with daunorubicin)
Description: 1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. High Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, Daunorubicin intrathecal methotrexate~3. High Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. High Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. High Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Allogeneic hematopoietic stem cell transplantation
Study: NCT05282615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emanate Tray
Description: Emanate Tray, a personalized dental tray set (upper and lower) with PVA hydrogel containing 0.05% w/w chlorhexidine gluconate
Study: NCT06223204

Intervention type: OTHER
Group type: OTHER
Intervention: Controlled euglycemia, hypoglycemia and hyperglycemia
Description: EIT measurements are collected in different glycemic states (euglycemia, hypoglycemia and hyperglycemia). Venous blood glucose is measured using a gold-standard glucose analyzer.
Study: NCT05001854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: 100 μg every 6 hours of fludrocortisone per os

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 μg every 6 hours of placebo per os
Study: NCT05197751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP3-CRM-Vac4All/ Alhydrogel®
Description: The Investigational Medicinal Product (IMP) or in short Investigational Product (IP) is the MSP3-CRM-Vac4All/ Alhydrogel® vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP3-CRM-Vac4All/ Alhydrogel®
Description: The Investigational Medicinal Product (IMP) or in short Investigational Product (IP) is the MSP3-CRM-Vac4All/ Alhydrogel® vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP3-CRM-Vac4All/ Alhydrogel®
Description: The Investigational Medicinal Product (IMP) or in short Investigational Product (IP) is the MSP3-CRM-Vac4All/ Alhydrogel® vaccine
Study: NCT06044844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: tofacitinib efficacy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: tofacitinib efficacy
Study: NCT05987722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enoxolone
Description: The experimental group returned home after the operation and used glycyrrhetinic acid toothpaste three times a day for oral cleaning.After the operation, toothpaste was used three times a day to clean the mouth for 12 weeks . Clinical evaluation was using the patient-reported pain score, painkillers, wound healing index (complete epithelization and color matching score), periodontal pocket depth, gingiva index, plaque index and were recorded before operation and 1st, 2nd, 3rd, 4th, 8th, 12th week after surgery. The control group used ordinary toothpaste for oral cleaning, and the rest of the research time, measurement time and measurement results were the same as the experimental group. During the study period, we will continue to monitor whether there is any adverse reaction, and if any adverse reaction occurs, the trial will be stopped.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensodyne
Description: The Active Comparator group returned home after the operation and used glycyrrhetinic acid -free toothpaste(Sensodyne) three times a day for oral cleaning. After the operation, toothpaste was used three times a day to clean the mouth for 12 weeks . Clinical evaluation was using the patient-reported pain score, painkillers, wound healing index (complete epithelization and color matching score), periodontal pocket depth, gingiva index, plaque index and were recorded before operation and 1st, 2nd, 3rd, 4th, 8th, 12th week after surgery. The control group used ordinary toothpaste for oral cleaning, and the rest of the research time, measurement time and measurement results were the same as the experimental group. During the study period, we will continue to monitor whether there is any adverse reaction, and if any adverse reaction occurs, the trial will be stopped.
Study: NCT06434389

Intervention type: DIAGNOSTIC_TEST
Intervention: the Electrochemical-based device
Description: Electrochemical-based device for rapid detection of fibrinogen is a novel POC diagnostic method, which is suitable for operating theatres and emergency rooms.
Study: NCT06236529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Behavior Change Counseling
Description: A telephone-based intervention employing principles and practices of motivational interviewing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management program
Description: An evidence-based 6-week SMP led by a registered nurse. The SMP was based on the Arthritis Self-Management Program and the Chronic Disease Self-Management Program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management program
Description: An evidence-based 6-week SMP led by a registered nurse. The SMP was based on the Arthritis Self-Management Program and the Chronic Disease Self-Management Program.
Study: NCT05802758

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychopathy.comp and training in virtual reality (VR)
Description: Psychopathy.comp is a CFT-based manualized program of 20 sessions a 60 min, on a weekly basis. During the CFT-intervention, partipants try out their new skills in a tailored VR setting (x5)
Study: NCT05283486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYMD-1 600MG
Description: Cohort 1: 600mg drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYMD-1 750mg
Description: Cohort 2: 750mg drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYMD-1 900mg
Description: Cohort 3: 900mg drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MYMD-1 1050mg
Description: Cohort 4: 1050mg drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 600mg
Description: Cohort 1: 600mg placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 750mg
Description: Cohort 2: 750mg placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 900mg
Description: Cohort 3: 900mg placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 1050mg
Description: Cohort 4: 1050mg placebo
Study: NCT05690100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GeliO3
Description: Anti-inflammatory Gel which has a beneficial role on wound healing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gingi gel
Description: Anti-inflammatory Gel which has a beneficial role on wound healing
Study: NCT05877625

Intervention type: PROCEDURE
Intervention: Expectoration care
Description: 1. Endotracheal aspiration: from discarded samples after expectoration care~2. BALF (bronchoalveolar lavage fluid): if patients with fiber bronchoscope examination, take the rest of the BALF after examination~3. Oropharyngeal swabs

Intervention type: PROCEDURE
Intervention: Expectoration care
Description: 1. Endotracheal aspiration: from discarded samples after expectoration care~2. BALF (bronchoalveolar lavage fluid): if patients with fiber bronchoscope examination, take the rest of the BALF after examination~3. Oropharyngeal swabs

Intervention type: PROCEDURE
Intervention: Expectoration care
Description: 1. Endotracheal aspiration: from discarded samples after expectoration care~2. BALF (bronchoalveolar lavage fluid): if patients with fiber bronchoscope examination, take the rest of the BALF after examination~3. Oropharyngeal swabs
Study: NCT04878731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: single dose SC injection of 300 mg PF-06741086
Study: NCT05083338

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Intervention: Pain Assessment
Description: Undergo pain assessment

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT06234254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality headset with calming scenery
Description: Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
Study: NCT06003946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BreLax: Antenatal education class
Description: An antenatal education class over 9 hours with information regarding pregnancy, labour and birth, pain management as well as the postpartum period with an integrated breathing and relaxation technique (prolonged exhalation in the individual rhythm) and 4 accompanying positions (standing upright, sitting supported, four-footed, supported lying on the side). In addition, participants receive a manual for independent practice at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care (control)
Description: An antenatal education class over 9 hours, with information regarding pregnancy, labour and birth, pain management and the postpartum period as well as some relaxation exercises.